587 related articles for article (PubMed ID: 17638033)
1. Economic evaluation for pharmaceuticals in Germany.
Jönsson B
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
[No Abstract] [Full Text] [Related]
2. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
3. Technology assessment in the German context.
Drummond M
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
[No Abstract] [Full Text] [Related]
5. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
6. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
7. [Expert evaluation of private drug prescriptions].
Kreck C; Saller R
Gesundheitswesen; 1995 May; 57(5):258-63. PubMed ID: 7620245
[TBL] [Abstract][Full Text] [Related]
8. Evaluation on the first 2 years of the positive list system in South Korea.
Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
[TBL] [Abstract][Full Text] [Related]
9. The efficiency frontier approach to economic evaluation: will it help German policy making?
Brouwer WB; Rutten FF
Health Econ; 2010 Oct; 19(10):1128-31. PubMed ID: 20641141
[No Abstract] [Full Text] [Related]
10. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
[TBL] [Abstract][Full Text] [Related]
11. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
Davidova J; Praznovcova L; Lundborg CS
Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
[TBL] [Abstract][Full Text] [Related]
12. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation and pharmaceutical reimbursement reform in South Korea's National Health Insurance.
Yang BM; Bae EY; Kim J
Health Aff (Millwood); 2008; 27(1):179-87. PubMed ID: 18180493
[TBL] [Abstract][Full Text] [Related]
14. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies.
Hailey D
Soc Sci Med; 1997 Aug; 45(4):563-81. PubMed ID: 9226782
[TBL] [Abstract][Full Text] [Related]
15. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA; Hill SR; Harris A
JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
[No Abstract] [Full Text] [Related]
16. Criteria and procedures for determining benefit packages in health care. A comparative perspective.
Gress S; Niebuhr D; Rothgang H; Wasem J
Health Policy; 2005 Jul; 73(1):78-91. PubMed ID: 15911059
[TBL] [Abstract][Full Text] [Related]
17. [Family physicians resist high prescription risk].
Schmidt K
MMW Fortschr Med; 2003 May; 145(20):58. PubMed ID: 12822233
[No Abstract] [Full Text] [Related]
18. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
Franken M; Koopmanschap M; Steenhoek A
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
[TBL] [Abstract][Full Text] [Related]
19. Implementing pharmacoeconomic guidelines in Latin America: lessons learned.
Augustovski F; Melendez G; Lemgruber A; Drummond M
Value Health; 2011; 14(5 Suppl 1):S3-7. PubMed ID: 21839895
[No Abstract] [Full Text] [Related]
20. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]